STOCK TITAN

Merit Medical Systems (MMSI) Stock News

MMSI NASDAQ

Merit Medical Systems Inc. develops, manufactures and distributes proprietary medical devices used in interventional, diagnostic and therapeutic procedures, with product activity concentrated in cardiology, radiology, oncology, critical care and endoscopy. Company news commonly covers operating results, annual guidance, revenue presentation by Foundational and Therapeutic product categories, and portfolio actions involving acquired or divested device lines.

Recurring updates also include commercial launches and distribution arrangements for products such as the Resilience Through-the-Scope Esophageal Stent, ViaVerte basivertebral nerve ablation system, OneMark Detection Imaging System and OneMark Tissue Markers. Governance announcements and healthcare conference participation appear alongside financial and product disclosures.

Rhea-AI Summary

Merit Medical Systems (MMSI) reported six-month WRAPSODY results from the arteriovenous fistula cohort of its global registry, covering 237 patients. The cohort spanned 31 sites in nine countries. Target lesion primary patency—freedom from specified repeat treatment or clotting at the treated site—was 92.7%, versus 89.8% in the WAVE pivotal trial. Access circuit primary patency, measuring maintenance of vascular access without reintervention or abandonment, was 76.7%, versus 72.8% in WAVE.

The prospective registry evaluates routine clinical use through 24 months after device placement. Results were presented on October 31, 2026, at the Controversies in Dialysis Access conference. A separate North American registry is designed to enroll up to 250 patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
-
Rhea-AI Summary

Merit Medical Systems (NASDAQ: MMSI) reported third-quarter 2026 revenue of $416.2 million, with higher earnings and an updated full-year outlook. Revenue increased 8.4% year over year; organic growth excluding currency effects was 9%. GAAP diluted earnings rose to $0.70 per share from $0.46, while GAAP operating margin increased to 14.1% from 11.1%. GAAP gross margin declined to 48.2% from 48.5%.

Merit expects 2026 revenue of $1.635–$1.642 billion, versus $1.631–$1.643 billion previously, and raised non-GAAP earnings guidance to $4.33–$4.37 per share from $4.25–$4.35. Nine-month operating cash flow was $175.2 million, with free cash flow of $129.5 million. Cash reached $503.6 million at September 30, versus $446.4 million at year-end; total debt obligations remained $747.5 million. Procedural Solutions and Renal Therapies revenue declined despite growth across the other product categories.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.66%
Tags
-
Rhea-AI Summary

Merit Medical Systems (NASDAQ: MMSI) acquired Solo Pace’s remaining equity for approximately $45 million on October 13, 2026, expanding its Cardiac Therapies platform. Solo Pace makes temporary pacing systems for transcatheter heart valve procedures, including transcatheter aortic valve replacement. Merit previously owned approximately 18% of Solo Pace.

Merit expects an immaterial impact on previously forecasted full-year 2026 revenue and GAAP and non-GAAP earnings. For 2027, it projects slightly higher non-GAAP net income and earnings per share, including approximately $1.5 million in lower interest income and excluding approximately $3.2 million in non-cash and non-recurring transaction-related expenses. GAAP net income and earnings per share are projected to be slightly diluted in 2027 and increased thereafter. Merit plans to expand U.S. adoption and, over time, international access.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.66%
Tags
Rhea-AI Summary

Merit Medical Systems (MMSI) will release its third-quarter 2026 financial results after the stock market closes on October 29, 2026. The results cover the quarter ended September 30, 2026. Merit plans to hold an investor conference call that day at 4:30 p.m. Eastern, with a live webcast and slide deck available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
earnings date
-
Rhea-AI Summary

Merit Medical (MMSI) will participate in several investor conferences in September 2026, including events hosted by Wells Fargo, Baird, Barrington Research, and Sidoti.

The Wells Fargo Healthcare Conference in Boston runs from September 8–10, with a fireside chat on September 10 at 8:45 a.m. Eastern Time. At the Baird Global Healthcare Conference in New York on September 15, management will present at 8:30 a.m. Eastern Time. The Barrington Research Virtual Fall Investment Conference on September 22 and the Sidoti Small Cap Conference on September 23–24 will feature management in 1x1 meetings only, with no formal presentations. Live audio webcasts and 90-day replays of the fireside chats will be available in the Events section of Merit’s investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
none
-
Rhea-AI Summary

Merit Medical Systems (NASDAQ: MMSI) appointed Sheri Lewis as Executive Vice President of Global Operations, effective August 31, 2026. She brings about 30 years of experience in global operations, manufacturing, and supply chain leadership at several major healthcare and industrial companies.

Current Chief Operating Officer Neil Peterson will transition to Senior Advisor through March 5, 2027, then conclude more than 32 years of service after holding multiple operations and engineering leadership roles.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
management
Rhea-AI Summary

Merit Medical (NASDAQ: MMSI) will participate in two August 2026 investor conferences. Management will join a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11 at 11:00 a.m. ET and at the Bank of America SMID Cap Conference, held virtually, on August 12 at 9:00 a.m. ET. Live audio webcasts and 90-day replays will be available in the Events section of Merit Medical’s investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.58%
Tags
none
-
Rhea-AI Summary

Merit Medical (NASDAQ:MMSI) reported second quarter 2026 revenue of $418.8 million, up 10% year-over-year, with constant currency and organic revenue each up 9%. U.S. sales grew 10%. GAAP gross margin improved to 51.4% and GAAP operating margin to 14.4%, while non-GAAP gross and operating margins reached 55.8% and 22.6%, respectively.

GAAP net income was $38.8 million (EPS $0.65), up 20%, and non-GAAP net income was $71.3 million (EPS $1.19), up 18%. Year-to-date operating cash flow was $110.0 million and free cash flow $76.6 million, down 11% and 14%. The company ended June 30, 2026 with $448.7 million in cash, $747.5 million in total debt, and about $697 million of available borrowing capacity. Merit raised its 2026 revenue guidance to $1.631–$1.643 billion (8% growth) and non-GAAP EPS guidance to $4.25–$4.35 (11–14% growth).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
-
Rhea-AI Summary

Merit Medical Systems (NASDAQ:MMSI) will release its second quarter 2026 financial results for the period ended June 30, 2026, after market close on Thursday, July 30, 2026. An investor conference call will follow at 4:30 p.m. Eastern, with webcast and registration links available at www.merit.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
earnings date
Rhea-AI Summary

Merit Medical (NASDAQ: MMSI) announced that shareholders elected Scott R. Ward to its Board of Directors at the May 19, 2026 annual meeting. Ward will serve a three-year term and join the Board’s Governance and Sustainability and Finance and Operating Committees.

Ward brings over 40 years of healthcare and medical device leadership, including senior roles at Medtronic, CEO and Chairman of Cardiovascular Systems during its sale to Abbott, and founder of Raymond Holdings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.20%
Tags
management

FAQ

What is the current stock price of Merit Medical Systems (MMSI)?

Merit Medical Systems (MMSI) last closed at $84.34.

What is the market cap of Merit Medical Systems (MMSI)?

The market cap of Merit Medical Systems (MMSI) is approximately $5.1B.